Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:38AM ET
3.09
Dollar change
+0.04
Percentage change
1.31
%
Index- P/E- EPS (ttm)-1.53 Insider Own59.08% Shs Outstand195.00M Perf Week1.64%
Market Cap691.79M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float91.60M Perf Month-11.97%
Income-319.30M PEG- EPS next Q-0.20 Inst Own10.02% Short Float5.30% Perf Quarter-27.12%
Sales45.75M P/S15.12 EPS this Y26.42% Inst Trans-2.61% Short Ratio6.00 Perf Half Y-56.54%
Book/sh2.85 P/B1.09 EPS next Y4.68% ROA-35.79% Short Interest4.86M Perf Year-51.91%
Cash/sh2.19 P/C1.41 EPS next 5Y-10.76% ROE-51.09% 52W Range2.76 - 12.36 Perf YTD-26.60%
Dividend Est.- P/FCF- EPS past 5Y-32.46% ROI-47.21% 52W High-75.00% Beta2.51
Dividend TTM- Quick Ratio3.41 Sales past 5Y72.72% Gross Margin-288.52% 52W Low11.96% ATR (14)0.18
Dividend Ex-Date- Current Ratio3.56 EPS Y/Y TTM-124.27% Oper. Margin-722.38% RSI (14)42.06 Volatility6.45% 5.55%
Employees1049 Debt/Eq0.07 Sales Y/Y TTM-57.32% Profit Margin-697.90% Recom1.89 Target Price12.89
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q6.41% Payout- Rel Volume0.52 Prev Close3.05
Sales Surprise-1.15% EPS Surprise0.76% Sales Q/Q58.86% EarningsNov 14 BMO Avg Volume808.99K Price3.09
SMA20-4.60% SMA50-9.60% SMA200-51.01% Trades Volume153,242 Change1.31%
Date Action Analyst Rating Change Price Target Change
Jun-08-23Initiated SVB Securities Outperform $13
Jan-19-23Upgrade UBS Neutral → Buy $8 → $18
Jan-09-23Upgrade Jefferies Hold → Buy $9 → $21
Jan-21-22Downgrade BofA Securities Neutral → Underperform $55 → $20
Jan-18-22Initiated JMP Securities Mkt Outperform $52
Oct-22-21Initiated Deutsche Bank Hold $35
Jun-17-21Downgrade BofA Securities Buy → Neutral $50
Apr-26-21Resumed Credit Suisse Underperform
Apr-26-21Initiated Guggenheim Neutral
Dec-10-20Downgrade Credit Suisse Neutral → Underperform $50 → $47
Feb-22-24 06:55PM
Jan-26-24 09:35AM
Jan-25-24 09:35AM
Jan-05-24 10:47AM
07:30AM
08:49AM Loading…
Dec-30-23 08:49AM
Dec-19-23 10:15PM
01:43PM
12:31PM
09:35AM
09:12AM
08:35AM
Nov-21-23 09:55AM
Nov-20-23 03:41PM
Nov-15-23 01:58PM
02:03AM Loading…
02:03AM
Nov-14-23 07:30AM
Nov-01-23 08:15AM
Oct-31-23 07:12PM
Sep-29-23 09:07AM
Sep-28-23 11:27AM
07:15AM
04:16AM
Sep-27-23 06:44PM
Sep-12-23 07:15AM
Aug-17-23 07:15AM
Aug-08-23 06:26AM
Aug-01-23 07:15AM
Jul-20-23 06:01AM
Jul-14-23 07:15AM
07:15AM Loading…
Jul-13-23 07:15AM
Jun-28-23 02:40PM
Jun-23-23 12:35PM
Jun-20-23 06:29PM
07:25AM
07:10AM
Jun-19-23 01:33PM
Jun-01-23 02:15PM
12:39PM
May-30-23 07:30AM
May-24-23 06:07AM
May-19-23 08:26AM
08:19AM
07:15AM
May-08-23 07:15AM
May-02-23 12:11AM
May-01-23 05:37PM
06:06AM
Apr-26-23 01:14AM
Apr-18-23 07:30AM
Apr-17-23 03:33PM
Mar-28-23 04:25PM
02:50PM
Mar-23-23 09:45AM
Mar-09-23 07:17PM
Feb-23-23 08:39AM
Feb-10-23 04:20PM
Feb-07-23 02:20AM
Feb-01-23 07:15AM
Jan-31-23 09:35AM
Jan-30-23 10:17AM
08:30AM
Jan-20-23 10:24AM
Jan-19-23 03:21PM
01:56PM
Jan-18-23 03:44PM
Jan-12-23 05:39AM
Jan-11-23 12:16PM
Jan-10-23 04:16PM
02:21PM
Jan-09-23 10:39AM
10:27AM
07:15AM
05:21AM
Jan-07-23 07:03AM
Jan-06-23 06:54PM
07:15AM
Dec-27-22 09:01AM
Dec-14-22 04:25PM
Nov-24-22 06:18AM
Nov-22-22 09:55AM
Nov-16-22 09:00AM
Nov-11-22 07:20AM
Nov-10-22 07:15AM
Oct-14-22 08:37AM
Sep-28-22 09:31AM
Sep-16-22 09:34AM
Sep-02-22 10:05AM
09:37AM
Aug-29-22 09:35AM
05:00AM
Aug-26-22 03:54PM
09:41AM
Aug-20-22 09:14AM
Aug-18-22 12:12PM
07:40AM
07:15AM
Jul-26-22 03:32PM
09:13AM
08:18AM
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mulbe in 2000 and is headquartered in Tubingen, Germany.